Comparative Pharmacology
Head-to-head clinical analysis: KLOR CON versus KLOROMIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOR CON versus KLOROMIN.
KLOR-CON vs KLOROMIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride acts as a source of potassium ions, which are essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium is the major cation of intracellular fluid and helps regulate acid-base balance.
KLOROMIN is a potassium-sparing diuretic that acts by antagonizing aldosterone in the distal renal tubules, inhibiting sodium reabsorption and potassium excretion.
Potassium chloride extended-release: 20-100 mEq per day orally, divided into 2-4 doses, titrated based on serum potassium and clinical response. Usual starting dose: 40 mEq per day.
1 g IV every 6 hours; infuse over 30 minutes.
None Documented
None Documented
The terminal elimination half-life of potassium is approximately 1-1.5 hours in healthy individuals with normal renal function. In patients with impaired renal function, half-life may be prolonged, increasing the risk of hyperkalemia.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extends to 20-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 50 hours in severe impairment (CrCl <30 mL/min).
Renal excretion of potassium ions accounts for approximately 90% of elimination via the kidneys, with the remaining 10% eliminated fecally. No biliary excretion is clinically significant.
Primarily renal (60-70% as unchanged drug, 10-20% as glucuronide conjugate), biliary/fecal (10-15% as metabolites).
Category C
Category C
Potassium Supplement
Potassium Supplement